C&R Research씨엔알리서치
359090 · KOSDAQ · ₩359090 · 씨엔알리서치
- Market cap
- ₩25B
- Enterprise value
- ₩27B
- P/E
- 15.0×
- P/B
- 0.5×
- Dividend yield
- 2.3%
- ROE
- 3.4%
- Net margin
- 2.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−63.1% from the high
₩1,667Today: ₩2,105 – ₩2,210₩5,890
Returns
- 1W−4.2%
- 1M−6.9%
- 3M+14.5%
- 6M−44.2%
- YTD−51.7%
- 1Y−54.3%
- Volume today
- 2,262
- 0.3× the 20-day average
- Traded today
- ₩4.9M
- Listed shares
- 11,494,143
- EPS (12 months)
- ₩145
- Earnings yield 6.6%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 27 of 100 (50 is a normal day for this stock).
- MomentumWeak-6% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
C&R Research stock overview
C&R Research (씨엔알리서치, KRX: 359090) is listed on KOSDAQ, in the Business services sector. The company is a Korean contract research organization (CRO) that provides clinical trial services to pharmaceutical companies and biotech ventures, covering the full range from trial design and protocol development to monitoring, data management, statistical analysis and reporting. Its shares closed at ₩2,175 on Oct 27, 2026, down 1.36% on the day, giving it a market value of ₩25B.
Key facts
- Market cap
- ₩25B
- Sector
- Business services
- Latest price change
- −1.36%
- As of
- Oct 27, 2026
- Main business
- The company is a Korean contract research organization (CRO) that provides clinical trial services to pharmaceutical companies and biotech ventures, covering the full range from trial design and protocol development to monitoring, data management, statistical analysis and reporting.
Quick answers about C&R Research
- What does C&R Research do?
- The company is a Korean contract research organization (CRO) that provides clinical trial services to pharmaceutical companies and biotech ventures, covering the full range from trial design and protocol development to monitoring, data management, statistical analysis and reporting. Its services span pre-approval trials (Phase I to III) and post-approval studies such as PMS and Phase IV, and it also develops clinical trial IT solutions through its subsidiary Trial Informatics. It operates mainly in South Korea, with stated plans to expand into global clinical trial markets.
- What is the market cap of C&R Research?
- The market capitalisation of C&R Research was ₩25B at the close on Oct 27, 2026.
- Who are the largest shareholders of C&R Research?
- According to the latest official filings, the largest reported holders are Yoon Moon-tae (63.27%, as of Jun 17, 2026); Yoon Byeong-in (21.82%, as of Jun 17, 2026); Choi Yun-jeong (0.14%, as of Jun 17, 2026).
- When is the next earnings report from C&R Research?
- Korean companies rarely announce results dates in advance. Based on when C&R Research filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company is a Korean contract research organization (CRO) that provides clinical trial services to pharmaceutical companies and biotech ventures, covering the full range from trial design and protocol development to monitoring, data management, statistical analysis and reporting. Its services span pre-approval trials (Phase I to III) and post-approval studies such as PMS and Phase IV, and it also develops clinical trial IT solutions through its subsidiary Trial Informatics. It operates mainly in South Korea, with stated plans to expand into global clinical trial markets.
Written by AI from the company's latest annual report.
- Korean name
- 씨엔알리서치
- Sector
- Business services
- CEO
- 윤문태
- Founded
- Jun 2020
- Listed
- Sep 2020
- Listed shares
- 11,494,143
- Fiscal year ends
- Month 12
- Website
- —
Similar companies
- S-1012750 · ₩3.6T₩95,300+2.14%
- Cheil Worldwide030000 · ₩2.2T₩19,010−0.83%
- Doosan Tesna131970 · ₩1.9T₩97,100+1.78%
- Lotte Tour Development032350 · ₩821B₩10,300+1.98%
- Soulbrain Holdings036830 · ₩772B₩37,650+4.73%
- Innocean Worldwide214320 · ₩694B₩17,360+0.52%
- Korea Ratings034950 · ₩458B₩100,8000.00%
- GC005250 · ₩425B₩9,030−0.66%
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Trading haltJun 29, 2026
- 5%+ holding reportJun 17, 2026
- Insider shareholding reportJun 17, 2026
- Insider shareholding reportJun 17, 2026
Titles in Korean until English translations are added.
Also known as: C&R Research / 씨엔알리서치 / 359090 / KRX:359090
Source: KRX statistical information